Ala.Ax
ALA.AX operates in the healthcare sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.
Business. ALA.AX operates in the healthcare sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ALA.AX operates in the healthcare sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.
The company maintains a strong liquidity position, with a current ratio of 14.18, indicating a significant ability to meet short-term obligations. However, the company is currently unprofitable, with a net income of -7,509,170 AUD and a return on equity of -0.374, which is below the industry median for profitability metrics. The company's capital structure is characterized by a debt-to-equity ratio of 0.0, suggesting a conservative approach to financing with no long-term debt.
In terms of profitability and returns, the company's return on assets of -0.3476 indicates a negative return on its asset base, which is a concern compared to industry benchmarks. The company's operating cash flow of -6,929,970 AUD and free cash flow of -7,814,780 AUD suggest that it is not generating sufficient cash from operations to sustain its activities without external financing.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration could pose a risk if the segment experiences a downturn. The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year.
The company's risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital expenditure of -412,900 AUD suggests a minimal investment in new assets, which may limit future growth opportunities.
Recent events, as disclosed in the company's filings, do not indicate any significant changes in the company's operations or financial position that would affect its future performance. The company's financial statements do not mention any recent strategic initiatives or product launches that could drive future revenue growth.
- The company has a strong liquidity position with a current ratio of 14.18.
- The company is currently unprofitable with a net income of -7,509,170 AUD.
- The company's capital structure is conservative with no long-term debt.
- The company's return on assets is negative, indicating a poor use of its asset base.
- The company's revenue is concentrated in a single segment, posing a risk to its financial stability.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ALA.AX Market data — financials · 2026-05-27